Updated: Reddy's Follows Endo On US Kuvan Launch

Sapropterin Market Worth Roughly $500m

 
• By Dean Rudge

Under the terms of a patent-litigation settlement from April 2017, Endo’s Par subsidiary has launched the first US generic versions of BioMarin’s Kuvan (sapropterin) tablet and powder formulations. Rival ANDA sponsor Dr Reddy’s has followed suit on the tablet formulation.

Red_Rocket
Both Endo and Reddy's have now launched generic Kuvan tablets following patent-litigation settlements • Source: Shutterstock

More from Products

More from Generics Bulletin